Serum GFAP autoantibody as an ELISA-detectable glioma marker

• DOI: 10.1007/s13277-013-0770-7
• Publication Date: 2013-04-15T04:18:18Z
• Authors: Ping Wei; Wei Zhang; Liu-Song Yang; Hai-Shi Zhang; Xiao-En Xu; Ying-Hua Jiang; Feng-Ping Huang; Qian Shi
• Keywords: 0301 basic medicine; 03 medical and health sciences; Brain Neoplasms; Glial Fibrillary Acidic Protein; Biomarkers, Tumor; Humans; Enzyme-Linked Immunosorbent Assay; Glioma; Autoantibodies; 3. Good health

Glioma is the most common primary brain tumor, yet high cost of diagnostic imaging has made early detection asymptomatic glioma a formidable challenge. Thus, development convenient, sensitive, and cost-effective strategy, such as enzyme-linked immunosorbent assay (ELISA) based on glioma-specific World Health Organization (WHO) grade-specific autoantibody serum markers, necessary. To this end, comparative proteomic analysis two-dimensional western blotting was carried out with sera patients normal controls. Of 11 novel glioma-expressed autoantibodies, against glial fibrillary acidic protein (GFAP) showed highest differential expression. investigate potential clinical utility GFAP an marker for glioma, ELISA-based developed validated from WHO grades II (n = 19), III 17), IV 24). The level directly correlated grade tumor volume. Sera non-glioma tumors, well non-brain much lower levels than those patients, indicating that elevated specific to patients. Analysis receiver operating characteristics curve suggested new ELISA good distinguishing power sensitivity diagnosing This first antigen may prove valuable glioma.